BRAF (v600e) and NRAS (q61r/q61l) mutation analysis using immunohistochemistry: Implications for routine mutation testing of melanoma samples

Hojabr Kakavand; Trina Lum; James S. Wilmott; Elizabeth Smith; Sandra O’Toole; Georgina V. Long; Richard A Scolyer

doi:10.1016/j.pathol.2015.12.349

Related publications

Article2012

Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma

Georgina V. Long, James S. Wilmott, David Capper, Matthias Preusser, Yuxiao E. Zhang, John F. Thompson, Richard Kefford, Andreas von Deimling, Richard A Scolyer

Article2012

BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma

Graham J. Mann, Gulietta M. Pupo, Anna Campain, Candace D. Carter, Sarah‐Jane Schramm, Svetlana Pianova, Sebastien K. Gerega, Chitra De Silva, Kenneth Lai, James S. Wilmott, Maria Synnott, Peter Hersey, Richard Kefford, John F. Thompson, Jean Yang, Richard A Scolyer

Article2014

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma

Matteo S. Carlino, Lauren E. Haydu, Hojabr Kakavand, Alexander M. Menzies, Anne Hamilton, Bing Yu, C C Ng, Wendy A. Cooper, John F. Thompson, Richard Kefford, Sandra O’Toole, Richard A Scolyer, Georgina V. Long

Article2021

BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

Richard A Scolyer, Victoria Atkinson, David Gyorki, Duncan Lambie, Sandra O’Toole, Robyn P.M. Saw, Benhur Amanuel, Christopher Angel, Alison Button‐Sloan, Matteo S. Carlino, Sydney Ch’ng, Andrew J. Colebatch, Dariush Daneshvar, Inês Pires da Silva, Tamara Dawson, Peter M. Ferguson, Erwin Foster‐Smith, Stephen B. Fox, Anthony J. Gill, Ruta Gupta, Michael A. Henderson, Angela Hong,

Article2012

Distinguishing Clinicopathologic Features of Patients with V600E and V600K <i>BRAF</i> -Mutant Metastatic Melanoma

Alexander M. Menzies, Lauren E. Haydu, Lydia Visintin, Matteo S. Carlino, Julie R. Howle, John F. Thompson, Richard Kefford, Richard A Scolyer, Georgina V. Long

BRAF (v600e) and NRAS (q61r/q61l) mutation analysis using immunohistochemistry: Implications for routine mutation testing of melanoma samples

Discussion(0)

Related publications

Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma

BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma

BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

Distinguishing Clinicopathologic Features of Patients with V600E and V600K <i>BRAF</i> -Mutant Metastatic Melanoma